Journal ArticleDOI
Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre Peter C,Chitra Suri,Pamela F. Jones,Sona Bartunkova,Stanley J. Wiegand,Czeslaw Radziejewski,Debra L Compton,Joyce Mcclain,Aldrich Thomas H,Nick Papadopoulos,Thomas J. Daly,Samuel Davis,Thomas N. Sato,George D. Yancopoulos +13 more
Reads0
Chats0
TLDR
The discovery of a negative regulator acting on Tie2 emphasizes the need for exquisite regulation of this angiogenic receptor system.Abstract:
Angiogenesis is thought to depend on a precise balance of positive and negative regulation. Angiopoietin-1 (Ang1) is an angiogenic factor that signals through the endothelial cell-specific Tie2 receptor tyrosine kinase. Like vascular endothelial growth factor, Ang1 is essential for normal vascular development in the mouse. An Ang1 relative, termed angiopoietin-2 (Ang2), was identified by homology screening and shown to be a naturally occurring antagonist for Ang1 and Tie2. Transgenic overexpression of Ang2 disrupts blood vessel formation in the mouse embryo. In adult mice and humans, Ang2 is expressed only at sites of vascular remodeling. Natural antagonists for vertebrate receptor tyrosine kinases are atypical; thus, the discovery of a negative regulator acting on Tie2 emphasizes the need for exquisite regulation of this angiogenic receptor system.read more
Citations
More filters
Journal ArticleDOI
Biochemistry and molecular cell biology of diabetic complications
TL;DR: This integrating paradigm provides a new conceptual framework for future research and drug discovery in diabetes-specific microvascular disease and seems to reflect a single hyperglycaemia-induced process of overproduction of superoxide by the mitochondrial electron-transport chain.
Journal ArticleDOI
Cell signaling by receptor-tyrosine kinases
TL;DR: Understanding of the complex signaling networks downstream from RTKs and how alterations in these networks are translated into cellular responses provides an important context for therapeutically countering the effects of pathogenic RTK mutations in cancer and other diseases.
Journal ArticleDOI
Mechanisms of angiogenesis and arteriogenesis.
TL;DR: The cellular and molecular mechanisms underlying the formation of endothelium-lined channels and their maturation via recruitment of smooth muscle cells (arteriogenesis) during physiological and pathological conditions are summarized, alongside with possible therapeutic applications.
Journal ArticleDOI
Angiogenesis in health and disease.
TL;DR: Molecular insights into the formation of new blood vessels are being generated at a rapidly increasing pace, offering new therapeutic opportunities that are currently being evaluated.
Journal ArticleDOI
Vascular-specific growth factors and blood vessel formation
George D. Yancopoulos,Samuel Davis,Nicholas W. Gale,John S. Rudge,Stanley J. Wiegand,Jocelyn Holash +5 more
TL;DR: New findings in newly discovered vascular growth factors demand re-evaluation of therapeutic efforts aimed at regulating blood vessel growth in ischaemia, cancer and other pathological settings.
References
More filters
Journal ArticleDOI
Angiogenesis in cancer, vascular, rheumatoid and other disease
TL;DR: Think of the switch to the angiogenic phenotype as a net balance of positive and negative regulators of blood vessel growth, which may dictate whether a primary tumour grows rapidly or slowly and whether metastases grow at all.
Journal ArticleDOI
Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis
TL;DR: The work from the authors' laboratories reviewed herein was supported by grants from the National Cancer Institute.
Journal ArticleDOI
Mechanisms of angiogenesis
TL;DR: Understanding of the molecular basis underlying angiogenesis, particularly from the study of mice lacking some of the signalling systems involved, has greatly improved, and may suggest new approaches for treating conditions such as cancer that depend onAngiogenesis.
Journal ArticleDOI
Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma
Michael S. O'Reilly,Michael S. O'Reilly,Lars Holmgren,Lars Holmgren,Yuen Shing,Yuen Shing,Catherine Chen,Catherine Chen,Rosalind A. Rosenthal,Rosalind A. Rosenthal,Marsha A. Moses,Marsha A. Moses,William S. Lane,Yihai Cao,E. Helene Sage,Judah Folkman +15 more
TL;DR: It is shown that the inhibition of metastases by a primary mouse tumor is mediated, at least in part, by angiostatin, and a corresponding fragment of human plasminogen has similar activity.
Journal ArticleDOI
Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis
Chitra Suri,Pamela F. Jones,Sybill Patan,Sona Bartunkova,Maisonpierre Peter C,Samuel Davis,Thomas N. Sato,George D. Yancopoulos +7 more
TL;DR: It is shown that mice engineered to lack Angiopoietin-1 display angiogenic deficits reminiscent of those previously seen in mice lacking TIE2, demonstrating that AngiopOietIn-1 is a primary physiologic ligand for TIE1 and that it has critical in vivo angiogenesis actions that are distinct from VEGF and that are not reflected in the classic in vitro assays used to characterize VEGf.